Como, 1 March 2023 – The University of Insubria is also part of the Immuno Hub project funded by the Ministry of Health and aimed at the prevention of infectious diseases and cancer. The goal is to develop a flexible national platform capable of providing a rapid response to new epidemiological needs, through the development of targeted biopharmaceuticals for immunotherapies. The skills, instruments and materials present in the seven project partners will be integrated and developed to offer an optimal path to deal with relevant infections and pathologies in the future. This project also aims to identify innovative solutions for the identification of biomarkers to be used in the epidemiological monitoring of infections and in the prognostic evaluation and response to tumor therapy. A multidisciplinary team from Insubria led by Professor Loredano Pollegioni will collaborate with Professor Marco Terreni of the University of Pavia, the researchers will tackle both infectious diseases (SARS-Cov-2 and tuberculosis) and oncological diseases, looking for predictive markers of response to anticancer treatments or related to primary or acquired resistance to immunotherapy. In particular, the Insubria researchers will be responsible for producing the proteins necessary to develop new anti-Covid and anti-tuberculosis vaccines and to develop a mucosal therapy. The researchers from the University of Insubria involved in the project are: Paolo Battaglia, Francesca Berini, Laura Caldinelli, Daniela Dalla Gasperina, Francesco Dentali, Mauro Fasano, Greta Forlani, Paolo Grossi, Gianluca Molla, Luciano Piubelli, Loredano Pollegioni, Elena Rosini, Silvia Sacchi. The project partners are: University of Pavia, University of Rome Tor Vergata, University of Insubria, IRCCS Foundation Policlinico San Matteo, Asst Fatebenefratelli Sacco, IRCCS Foundation National Cancer Institute, Scuola Normale Superiore of Pisa.